Bausch + Lomb has decided to discontinue development of its investigational glaucoma eye drop BL1107 after the treatment failed to meet the primary objective in a phase 2 clinical trial.
The company had been testing BL1107, an alpha-2B agonist, in a mid-stage study involving 159 patients with primary open-angle glaucoma or ocular hypertension. The trial was designed to determine whether the treatment could improve visual sensitivity from baseline by Day 28. According to the company, the study did not achieve its primary endpoint. In addition, key secondary endpoints evaluating visual function were also not met.
The outcome contrasted with findings from an earlier phase 1/2a study, which had indicated potential for the candidate. Bausch + Lomb disclosed the latest results in a post-market announcement on July 9 and confirmed that it would stop pursuing the eye drops for glaucoma-related vision improvement.
BL1107 became part of Bausch + Lomb’s pipeline through its acquisition of Whitecap Biosciences last year. The transaction included an upfront payment of $28 million and brought two investigational programs into the company’s portfolio. Alongside BL1107, the deal also included WB006, a sustained-release implant version of the same alpha-2B agonist that is being developed for geographic atrophy.
At the time of the acquisition, Bausch + Lomb had highlighted the potential of Whitecap’s programs in addressing vision loss. Following the phase 2 setback for BL1107, the company said it will now direct its attention toward development of the implant program.
The sustained-release implant is being developed for geographic atrophy, an advanced form of dry age-related macular degeneration in which cells in the macula of the retina progressively die. Bausch + Lomb said it intends to continue pursuing the implant for vision-threatening diseases, with geographic atrophy serving as the primary focus.
The company expects clinical trials for the implant to begin in 2028. Development of the candidate is planned in collaboration with Ripple Therapeutics, whose controlled-release drug technology is expected to be used in the program.
If successfully developed, the implant could become the first small-molecule sustained-release implant for geographic atrophy.
Bausch + Lomb already markets several products for glaucoma treatment, including Vyzulta, a latanoprostene bunod ophthalmic solution, and Istalol, a timolol maleate ophthalmic solution. BL1107 had been viewed as a significant investigational candidate within the company’s glaucoma portfolio before the phase 2 results were reported.
Commenting on the decision, Chief Medical Officer Yehia Hashad said the company’s research strategy is based on advancing multiple programs rather than relying on a single candidate. Hashad stated, “Success in drug development is based on a portfolio, not a single program.” He also said the company had deliberately built a diversified pipeline because innovation requires testing multiple scientific approaches at the same time, adding that not every program succeeds but that each study provides information that helps guide future investment decisions.
Following the announcement, U.S.-listed shares of Bausch + Lomb were down 2.8% in extended trading.
Bausch + Lomb has announced the discontinuation of its BL1107 glaucoma development program after the investigational therapy failed to meet the primary endpoint in a Phase 2 clinical trial. The decision reflects the company’s commitment to prioritizing programs with the strongest scientific and clinical potential while continuing to invest in innovation across its eye care portfolio.
Phase 2 Trial Did Not Meet Primary Endpoint
The Phase 2 study evaluated the safety and effectiveness of BL1107 in patients with glaucoma. According to Bausch + Lomb, the trial did not achieve its primary efficacy goal, making it difficult to justify continued development of the candidate.
Although the study provided valuable clinical data, the outcome did not support advancing the program into later-stage trials.
Bausch + Lomb Reports Phase 2 Trial Results
Although BL1107 will no longer be developed, Bausch + Lomb is expected to continue investing in ophthalmology innovation, including treatments for glaucoma, retinal diseases, and other eye conditions. The company’s long-term strategy remains focused on delivering advanced solutions that improve vision and patient care.
Future pipeline updates may include new therapies supported by emerging technologies and clinical research.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
